Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Refractory Solid Tumors

Refractory Solid Tumors

44

Pipeline Programs↗

26

Active Trials↗

51

Companies Involved↗

Refractory Solid Tumors is a moderately active landscape with 44 programs across 51 companies. The most active players are Immatics Biotechnologies GmbH, Sorrento Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

22/100

Mech. Concentration

11/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Immatics Biotechnologies GmbH

2 programs

Sorrento Therapeutics, Inc.

1 program

Pipeline

Programs by Phase

Preclinical2

Xya02

XYone Therapeutics, Inc

PEEL-224

Peel Therapeutics Inc

Phase 118

Cabozantinib

Bristol-Myers Squibb

GV20-0251

GV20 Therapeutics

Second Generation 4-1BBζ EGFR806-Egfrt

Seattle Children's Hospital

STI-1386

Sorrento Therapeutics, Inc.

B7-H3CART Dose (intravenous)

Crystal Mackall, MD

Phase 224

Nivolumab

Bristol-Myers Squibb

Palbociclib

Pfizer

Irinotecan

Pfizer

Mitoxantrone Liposome

The First Affiliated Hospital of Soochow University

Devimistat

Northwestern University

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

75%

Small molecule

30 of 40 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 98% of 44 pipeline programs.

Analysis

Trial Status

185

clinical trials

Completed118 · 64%

Recruiting17 · 9%

Unknown status14 · 8%

Terminated13 · 7%

Withdrawn11 · 6%

Not yet recruiting6 · 3%

Other6 · 3%

Clinical Trials

Trial Activity

185 trials

A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors

Recruiting·—·Preclinical·NCT06721689·59 enrolled

A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors

Recruiting·XXYone Therapeutics, Inc·Preclinical·NCT07670312·190 enrolled

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Combination With Hydroxyurea or Hydroxyurea/Atezolizumab in Treatment-refractory Solid Tumor Patients

Recruiting·BBionoxx Inc.·Phase 1·NCT07190833·27 enrolled

ELEVATE Study: A Phase II Single-Arm Open-Label Single-Center Exploratory Trial of Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Advanced Refractory Solid Tumors With EGFR-Positive

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT07712029·32 enrolled

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

Recruiting·—·Phase 1·NCT06500819·41 enrolled

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Recruiting·IImmatics Biotechnologies GmbH·Phase 1·NCT05359445·95 enrolled

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Recruiting·—·Phase 1·NCT03611595·18 enrolled

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Recruiting·—·Phase 1·NCT06612645·9 enrolled

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06006273·48 enrolled

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Recruiting·WWashington University School of Medicine·Phase 1·NCT05521984·20 enrolled

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Recruiting·NNorthwestern University·Phase 2·NCT05733000·94 enrolled

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Recruiting·IImmatics US, Inc.·Phase 1/2·NCT03686124·375 enrolled

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Recruiting·WWest China Hospital·Phase 1·NCT07106827·10 enrolled

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Recruiting·TTianjin Medical University Second Hospital·Phase 1/2·NCT06895733·65 enrolled

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT04796012·23 enrolled

Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)